Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight
Abstract Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-18309-2 |
| _version_ | 1811297385335226368 |
|---|---|
| author | Oliver C. Watkins Preben Selvam Reshma Appukuttan Pillai Victoria K. B. Cracknell-Hazra Hannah E. J. Yong Neha Sharma Amaury Cazenave-Gassiot Anne K. Bendt Keith M. Godfrey Rohan M. Lewis Markus R. Wenk Shiao-Yng Chan |
| author_facet | Oliver C. Watkins Preben Selvam Reshma Appukuttan Pillai Victoria K. B. Cracknell-Hazra Hannah E. J. Yong Neha Sharma Amaury Cazenave-Gassiot Anne K. Bendt Keith M. Godfrey Rohan M. Lewis Markus R. Wenk Shiao-Yng Chan |
| author_sort | Oliver C. Watkins |
| collection | DOAJ |
| description | Abstract Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention for gestational diabetes (GDM), we aimed to determine whether myo-inositol could rectify perturbations in placental DHA metabolism associated with maternal increasing glycemia and obesity and examine links with birthweight. Term placental villous explants from 17 women representing a range of BMIs and mid-gestational glycemia, were incubated with 13C-labeled-DHA for 48 h, in 0.3 µmol/L (control) or 60 µmol/L myo-inositol. Individual newly synthesized 13C-DHA-labeled lipid species were quantified by liquid-chromatography-mass-spectrometry. Compared with controls, incubation with myo-inositol decreased most 13C-DHA-lipids in placental explants from women with higher BMI or higher glycemia, but increased 13C-DHA-lipids with normal BMI or lower glycemia. Myo-inositol also increased 13C-DHA-labeled lipids in cases of lower birthweight centile, but induced decreases at higher centiles. Myo-inositol therefore lowered DHA-lipids in placenta with high basal placental DHA-lipid production (higher BMI and glycemia) but increased DHA-lipids where basal processing capacity is low. Myo-inositol thus moderates placental DHA metabolism towards a physiological mean which may in turn moderate birthweight. |
| first_indexed | 2024-04-13T06:03:26Z |
| format | Article |
| id | doaj.art-9ebbcd9015ba45948a66e5716d3de860 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-13T06:03:26Z |
| publishDate | 2022-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-9ebbcd9015ba45948a66e5716d3de8602022-12-22T02:59:22ZengNature PortfolioScientific Reports2045-23222022-09-0112111410.1038/s41598-022-18309-2Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweightOliver C. Watkins0Preben Selvam1Reshma Appukuttan Pillai2Victoria K. B. Cracknell-Hazra3Hannah E. J. Yong4Neha Sharma5Amaury Cazenave-Gassiot6Anne K. Bendt7Keith M. Godfrey8Rohan M. Lewis9Markus R. Wenk10Shiao-Yng Chan11Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health SystemDepartment of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health SystemDepartment of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health SystemDepartment of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health SystemSingapore Institute for Clinical Sciences, Agency for Science, Technology and ResearchDepartment of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health SystemDepartment of Biochemistry, Yong Loo Lin School of Medicine, National University of SingaporeSingapore Lipidomics Incubator, Life Sciences Institute, National University of SingaporeFaculty of Medicine, University of SouthamptonFaculty of Medicine, University of SouthamptonDepartment of Biochemistry, Yong Loo Lin School of Medicine, National University of SingaporeDepartment of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health SystemAbstract Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention for gestational diabetes (GDM), we aimed to determine whether myo-inositol could rectify perturbations in placental DHA metabolism associated with maternal increasing glycemia and obesity and examine links with birthweight. Term placental villous explants from 17 women representing a range of BMIs and mid-gestational glycemia, were incubated with 13C-labeled-DHA for 48 h, in 0.3 µmol/L (control) or 60 µmol/L myo-inositol. Individual newly synthesized 13C-DHA-labeled lipid species were quantified by liquid-chromatography-mass-spectrometry. Compared with controls, incubation with myo-inositol decreased most 13C-DHA-lipids in placental explants from women with higher BMI or higher glycemia, but increased 13C-DHA-lipids with normal BMI or lower glycemia. Myo-inositol also increased 13C-DHA-labeled lipids in cases of lower birthweight centile, but induced decreases at higher centiles. Myo-inositol therefore lowered DHA-lipids in placenta with high basal placental DHA-lipid production (higher BMI and glycemia) but increased DHA-lipids where basal processing capacity is low. Myo-inositol thus moderates placental DHA metabolism towards a physiological mean which may in turn moderate birthweight.https://doi.org/10.1038/s41598-022-18309-2 |
| spellingShingle | Oliver C. Watkins Preben Selvam Reshma Appukuttan Pillai Victoria K. B. Cracknell-Hazra Hannah E. J. Yong Neha Sharma Amaury Cazenave-Gassiot Anne K. Bendt Keith M. Godfrey Rohan M. Lewis Markus R. Wenk Shiao-Yng Chan Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight Scientific Reports |
| title | Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight |
| title_full | Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight |
| title_fullStr | Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight |
| title_full_unstemmed | Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight |
| title_short | Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight |
| title_sort | myo inositol moderates maternal bmi and glycemia related variations in in vitro placental 13c dha metabolism altering their relationships with birthweight |
| url | https://doi.org/10.1038/s41598-022-18309-2 |
| work_keys_str_mv | AT olivercwatkins myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT prebenselvam myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT reshmaappukuttanpillai myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT victoriakbcracknellhazra myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT hannahejyong myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT nehasharma myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT amaurycazenavegassiot myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT annekbendt myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT keithmgodfrey myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT rohanmlewis myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT markusrwenk myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight AT shiaoyngchan myoinositolmoderatesmaternalbmiandglycemiarelatedvariationsininvitroplacental13cdhametabolismalteringtheirrelationshipswithbirthweight |